BR100 Decreased By (-0.25%)
BR30 Decreased By (-0.64%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.83 Decreased By ▼ -0.20 (-3.32%)
BML 57.90 Increased By ▲ 5.15 (9.76%)
BOP 33.79 Decreased By ▼ -0.46 (-1.34%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.79 Decreased By ▼ -0.55 (-4.46%)
FCCL 53.49 Decreased By ▼ -0.40 (-0.74%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.84 Decreased By ▼ -0.19 (-1.05%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.11 Increased By ▲ 0.11 (1%)
KEL 8.02 Decreased By ▼ -0.09 (-1.11%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.40 Decreased By ▼ -0.65 (-0.74%)
NBP 184.24 Decreased By ▼ -2.24 (-1.2%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.25 Increased By ▲ 0.31 (0.78%)
PIAHCLA 26.12 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.14 Decreased By ▼ -0.18 (-1.04%)
PPL 228.73 Decreased By ▼ -4.05 (-1.74%)
PRL 34.49 Decreased By ▼ -0.46 (-1.32%)
PTC 67.54 Decreased By ▼ -0.02 (-0.03%)
SEARL 90.93 No Change ▼ 0.00 (0%)
SSGC 26.83 Decreased By ▼ -0.34 (-1.25%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.33 Increased By ▲ 0.57 (6.51%)
TREET 24.51 Decreased By ▼ -0.03 (-0.12%)
TRG 71.61 Decreased By ▼ -0.14 (-0.2%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
Business & Finance

Novartis more upbeat on 2025 guidance after strong Q1 momentum

Published April 29, 2025 Updated April 29, 2025 11:18am
Save
1 min
comment
By Reuters
Add BRecorder as a trusted
source on Google
Google Preferred Source

FRANKFURT: Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.

The Swiss drugmaker said in a statement that it expects 2025 operating income, adjusted for special items, to grow by a “low double-digit” percentage.

Novartis agrees to acquire Anthos for up to $3.1 billion

It had previously projected “high single to low double-digit” growth, compared with a 22% increase in 2024.

Novartis

Comments

Comments are closed for this article.

More Stories

Browse all stories